AbbVie Wary Of IRA Potential Impact On Struggling Imbruvica

While AbbVie tries to estimate which of its products might fall into CMS price negotiations, it is seeing lower-than-expected sales erosion for Humira and continued growth for Skyrizi and Rinvoq.

AbbVie Building
AbbVie's projections of Humira sales erosion are holding up well • Source: Shutterstock (Valeriya Zankovych/Shutterstock)

AbbVie Inc. reported solid second quarter 2023 financial performance on 27 July, with US biosimilar erosion for Humira a bit lower than the company projected while immunology successors Skyrizi and Rinvoq showed strong growth and price stabilization in the US. But CEO Rick Gonzalez pointed to one of AbbVie’s struggling core products, Imbruvica, as one that could be a target of the first Medicare price negotiations this fall under the Inflation Reduction Act (IRA).

Imbruvica (ibrutinib), a BTK inhibitor partnered with Johnson & Johnson, posted a 25% revenue decline during Q1 due to...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.